

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Insulin Glargine Formulation

Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road
HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : Crystalline powder

Colour : white

Odour : No data available

May be harmful if swallowed. Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life.

GHS Classification

Acute toxicity (Oral) : Category 5

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 1

Specific target organ toxicity - repeated exposure : Category 2

Short-term (acute) aquatic hazard : Category 3

GHS label elements

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
7.0	2025/04/14	42880-00028	2024/09/28
			Date of first issue: 2015/01/07

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	H303 May be harmful if swallowed. H315 Causes skin irritation. H318 Causes serious eye damage. H373 May cause damage to organs through prolonged or repeated exposure. H402 Harmful to aquatic life.
Precautionary statements	:	Prevention: P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P273 Avoid release to the environment. P280 Wear protective gloves/ eye protection/ face protection. Response: P301 + P332 + P317 IF SWALLOWED or if skin irritation occurs: Get medical help. P302 + P352 IF ON SKIN: Wash with plenty of water. P305 + P354 + P338 + P317 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Get medical help. P319 Get medical help if you feel unwell. P362 + P364 Take off contaminated clothing and wash it before reuse. Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

May be harmful if swallowed. Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Harmful to aquatic life.

Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Components

Chemical name	CAS-No.	Concentration (% w/w)
Insulin Glargine	160337-95-1	≥ 90 - ≤ 100
m-Cresol	108-39-4	≥ 3 - < 5

4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May be harmful if swallowed. Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version 7.0 Revision Date: 2025/04/14 SDS Number: 42880-00028 Date of last issue: 2024/09/28
Date of first issue: 2015/01/07

- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents
- Storage**
- Conditions for safe storage : Keep in properly labelled containers.
Keep tightly closed.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Insulin Glargine	160337-95-1	TWA	3 µg/m ³ (OEB 4)	Internal
m-Cresol	108-39-4	PC-TWA	10 mg/m ³	CN OEL
Further information: Skin				
		TWA (Inhalable fraction and vapor)	20 mg/m ³	ACGIH

- Engineering measures** : Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Filter type	:	ommended guidelines, use respiratory protection.
Eye/face protection	:	Combined particulates and organic vapour type
	:	Wear the following personal protective equipment:
	:	Chemical resistant goggles must be worn.
	:	If splashes are likely to occur, wear:
	:	Face-shield
Skin and body protection	:	Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
	:	Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
	:	When using do not eat, drink or smoke.
	:	Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Crystalline powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	No data available

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 3,025 mg/kg
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Insulin Glargine:

Acute oral toxicity : Remarks: No data available

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

m-Cresol:

Acute oral toxicity : LD50 (Rat): 121 mg/kg
Remarks: Based on data from similar materials

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

Acute dermal toxicity : LD50 (Rabbit): 301 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Causes skin irritation.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit

Result : Corrosive after 3 minutes to 1 hour of exposure

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Insulin Glargine:

Remarks : No data available

m-Cresol:

Species : Rabbit
Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Insulin Glargine:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Insulin Glargine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Result: negative
Remarks: Based on data from similar materials

m-Cresol:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Genotoxicity in vivo	Result: negative
:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
:	Species: Mouse
:	Application Route: Ingestion
:	Method: OECD Test Guideline 475
:	Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Insulin Glargine:

Species	: Rat
Exposure time	: 2 Years
NOAEL	: 0.455 mg/kg body weight
Result	: negative

Species	: Mouse
Exposure time	: 2 Years
NOAEL	: 0.455 mg/kg body weight
Result	: negative

m-Cresol:

Species	: Mouse, males
Application Route	: Ingestion
Exposure time	: 105 weeks
Result	: equivocal
Remarks	: Based on data from similar materials

Species	: Mouse, female
Application Route	: Ingestion
Exposure time	: 106 - 107 weeks
Result	: positive
Remarks	: Based on data from similar materials

Carcinogenicity - Assessment	: Weight of evidence does not support classification as a carcinogen
------------------------------	--

Reproductive toxicity

Not classified based on available information.

Components:

Insulin Glargine:

Effects on fertility	: Test Type: Fertility/early embryonic development
:	Species: Rat
:	Application Route: Subcutaneous

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

	Fertility: NOAEL: 0.36 mg/kg body weight Result: No effects on fertility
	Test Type: Fertility/early embryonic development Species: Rabbit Application Route: Subcutaneous Fertility: NOAEL: 0.072 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 0.36 mg/kg body weight Result: No effects on foetal development
	Species: Rabbit Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.072 mg/kg body weight Result: Fetotoxicity Remarks: The mechanism or mode of action may not be relevant in humans.

m-Cresol:

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	: Test Type: Prenatal development toxicity study (teratogenicity) Species: Rat Application Route: Ingestion Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Insulin Glargine:

Exposure routes	: Ingestion
Target Organs	: Blood, Nervous system
Assessment	: May cause damage to organs through prolonged or repeated exposure.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Repeated dose toxicity

Components:

Insulin Glargine:

Species	: Rat
NOAEL	: 0.5 mg/kg
LOAEL	: 1.5 mg/kg
Application Route	: Subcutaneous
Exposure time	: 30 d
Target Organs	: Blood, Nervous system

m-Cresol:

Species	: Rat
NOAEL	: 150 mg/kg
Application Route	: Ingestion
Exposure time	: 13 Weeks
Method	: OECD Test Guideline 408

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Insulin Glargine:

Inhalation	: Target Organs: Blood Symptoms: Hypoglycemia, Headache, Sweating, Tremors, Nausea
------------	---

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

m-Cresol:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 8.6 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l Exposure time: 48 h
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 1.35 mg/l Exposure time: 32 d Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates (Chronic)	: NOEC (Daphnia magna (Water flea)): 1 mg/l Exposure time: 21 d

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Acute toxicity)

Remarks: Based on data from similar materials

Persistence and degradability

Components:

m-Cresol:

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 90 % Exposure time: 28 d Method: OECD Test Guideline 301D
------------------	---	---

Bioaccumulative potential

Components:

m-Cresol:

Bioaccumulation	:	Species: Leuciscus idus (Golden orfe) Bioconcentration factor (BCF): 17 - 20
Partition coefficient: n-octanol/water	:	log Pow: 1.96

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

IATA-DGR

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Packing instruction (cargo aircraft)	: Not applicable
Packing instruction (passenger aircraft)	: Not applicable

IMDG-Code

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Marine pollutant	: no

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals	: This product is not listed in the catalogue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination.
----------------------------------	---

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

18218)

Hazardous Chemicals for Priority Management under SAWS : Not listed

Catalogue of Specially Controlled Hazardous Chemicals : Not listed

List of Explosive Precursors : Not listed

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed

List of Controlled Ozone Depleting Substances : Not listed

Environmental Protection Law

List of Priority Controlled Chemicals : Not listed

List of Key Controlled New Pollutants : Not listed

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2025/04/14

Further information

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
CN OEL : Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.

ACGIH / TWA : 8-hour, time-weighted average
CN OEL / PC-TWA : Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
7.0	2025/04/14	42880-00028	Date of first issue: 2015/01/07

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN